The Prognostic Value of ADAMTS-13 and von Willebrand Factor in COVID-19 Patients: Prospective Evaluation by Care Setting

Giovanni Tiscia 1, Giovanni Favuzzi 1, Antonio De Laurenzo 1, Filomena Cappucci 1, Lucia Fischetti 1, Donatella Colaizzo 1, Elena Chinni 1, Lucia Florio 2, Giuseppe Miscio 3, Angela Pamela Piscitelli 4, Mario Mastroianno 5,6 and Elvira Grandone 1,6,* on behalf of the CSS COVID-19 Group

Abstract: Background: Endothelial dysfunction, coupled with inflammation, induces thromboinflammation. In COVID-19, this process is believed to be associated with clinical severity. Von Willebrand factor (VWF), and a disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS-13), are strong markers of endothelial dysfunction. We evaluated the impact of the VWF/ADAMTS-13 fraction on COVID-19 severity and prognosis. Materials and methods: A cohort study including 74 COVID-19 patients, with 22 admitted to the intensive care unit (ICU) and 52 to the medical ward (MW), was carried out. We also evaluated, in a group of 54 patients who were prospectively observed, whether variations in VWF:RCo/ADAMTS-13 correlated with the degree of severity and routine blood parameters. Results: A VWF:RCo/ADAMTS-13 fraction above 6.5 predicted in-hospital mortality in the entire cohort. At admission, a VWF:RCo/ADAMTS-13 fraction above 6.5 predicted admission to the ICU. Furthermore, the VWF:RCo/ADAMTS-13 fraction directly correlated with C-reactive protein (CRP) (Spearman r: 0.51, p < 0.0001) and D-dimer (Spearman r: 0.26, p = 0.03). In the prospective cohort, dynamic changes in VWF:RCo/ADAMTS-13 and the CRP concentration were directly correlated (Spearman r, p = 0.0014). This relationship was significant in both groups (ICU: p = 0.006; MW: p = 0.02). Conclusions: The present findings show that in COVID-19, the VWF/ADAMTS-13 fraction predicts in-hospital mortality. The VWF/ADAMTS-13 fraction may be a helpful tool to monitor COVID-19 patients throughout hospitalization.

Keywords: COVID-19; endothelium; von Willebrand factor; ADAMTS-13; fatalities

1. Introduction

The number of published papers on the new viral disorder COVID-19 has now exceeded the threshold of 80,000. Several studies focused on prognostic aspects, and a large portion of them reported an association between COVID-19 severity and significant changes in hemostasis and coagulation markers.
Several studies found that D-dimer predicts mortality, as it progressively increases in those who develop the most severe clinical spectrum [1–3]. It has been hypothesized that the mechanisms for the increased D-dimer in COVID-19 may be related to the virus life cycle. The apoptotic process targets the endothelial cells, which results in activation of coagulation and, in turn, in the increase in D-dimer [4].

Previous reports showed a significant increase in the markers of endothelial dysfunction in COVID-19. For instance, von Willebrand factor (VWF) levels and high-molecular-weight multimers are mainly observed in the most-critical patients [5,6]. On the other hand, hyper-inflammation may also contribute to the endothelial dysfunction in COVID-19 [7].

Therefore, there is a strong relationship between endothelial injury, the inflammation process, activation of the coagulation cascade, and the severity of the disease. Consistent with this, several studies documented an association between reduced activity levels of ADAMTS-13 and mortality [8,9]. We previously found that ADAMTS-13, at hospital admission, predicts mortality in COVID-19 patients [10]. Indeed, as for septic patients, low ADAMTS-13 levels are inversely correlated with VWF and a poor prognosis [11].

The aims of the present study were as follows: (1) to compare the VWF/ADAMTS-13 fraction in COVID-19 patients according to the care setting, and explore the relationship between these parameters and inflammatory markers; (2) to prospectively evaluate whether, and to what extent, the VWF/ADAMTS-13 fraction is predictive of mortality.

2. Materials and Methods

2.1. Study Methodology and Setting

We enrolled 74 patients consecutively observed between 1 March and 30 September 2020, with a laboratory-confirmed SARS-CoV-2 infection (i.e., RT-PCR according to the protocol established by the WHO). In all cases, we collected at baseline all relevant demographic/clinical information and routine panel blood parameters. Exclusion criteria were as follows: age below 18 years, pregnancy, confirmed VWF disease.

We compared findings from patients admitted to the intensive care unit (ICU) to those observed in patients hospitalized in the medical ward (MW). Furthermore, we tested a possible relationship of VWF and ADAMTS-13 with a poor prognosis.

In a group of 54 patients prospectively observed, we also evaluated whether variations [calculated as Δ (delta: in-hospital changes)] value on blood samples collected after at least five days from the baseline] in VWF/ADAMTS-13 correlated with the degree of severity and routine blood parameters. The study was approved by our ethics committee and carried out in accordance with the lastly amended Helsinki Declaration.

2.2. Sample Preparation and Plasma-Based Determinations

Venous blood was collected into 0.1 vol. 0.129 M sodium citrate and platelet-poor plasma was prepared by centrifugation of 10 min at 1600 × g and stored in aliquots. VWF:RCo and VWF:Ag were measured, using an automated latex immunoassay in human citrated plasma on ACL TOP® coagulation systems (HemosIL®). ADAMTS-13 activity was measured, using a chromogenic ELISA assay (TECHNOZYM® ADAMTS-13 activity ELISA kit, Technoclone, Vienna, Austria) as previously described [12].

2.3. Data Analysis

Categorical variables were described as numbers and percentages. Normal variables were summarized as means and standard deviations, and non-normal variables as medians and interquartile range (IQR). We used the χ² test, Fisher’s exact test, or Mann–Whitney U test to compare differences where appropriate according to data distribution, examined by means of the D’Agostino & Pearson test. Significance was set at p values below 0.05.
3. Results

3.1. Demographic/Clinical Information and Laboratory Data

Among the 74 patients recruited (all patients were Caucasian), 22 were hospitalized in the ICU and 52 in the MW. Table 1 depicts the demographic and clinical information of the entire cohort. The patients admitted to the ICU were significantly younger than those admitted to the MW, with a higher proportion of males in the ICU (77% vs. 50%). Furthermore, the two groups were similar with regard to the pre-existing co-morbidities and fatalities (Table 1). As far as routine blood parameters are concerned, the white blood cells (WBC), neutrophil-to-lymphocyte ratio (NRL), lactate dehydrogenase (LDH), direct bilirubin, alanine aminotransferase (ALT), activated partial thromboplastin time (aPTT), fibrinogen, D-dimer, and factor VIII were significantly different according to the care setting (Table 1).

Table 1. Comparison of demographic/clinical information and blood parameters in patients admitted to ICU or medical ward.

| Variables                                      | All, n = 74 | ICU, n = 22 | Medical Ward, n = 52 | p Value |
|------------------------------------------------|-------------|-------------|-----------------------|---------|
| Age, years, (IQR)                              | 68.0 (22.0) | 63.0 (15.2) | 69.0 (19.7)           | 0.03    |
| Male, n (%)                                    | 43 (58)     | 17 (77)     | 26 (50)               | 0.02    |
| Deaths, n (%)                                  | 26 (35.0)   | 10 (45.5)   | 16 (30.7)             | 0.19    |
| Invasive ventilation, n (%)                    | 11 (15)     | 11 (50)     | 0 (0)                 | <0.0001 |
| Non-invasive ventilation, n (%)                | 30 (40.5)   | 11 (50)     | 19 (36.5)             | 0.31    |
| Diabetes, n (%)                                | 15 (20)     | 6 (27.3)    | 9 (17.3)              | 0.35    |
| Hypertension, n (%)                            | 36 (48.5)   | 11 (50)     | 25 (48)               | 0.90    |
| Chronic Kidney Disease, n (%)                  | 11 (15)     | 6 (27.3)    | 6 (11.5)              | 0.16    |
| Cardiovascular disease, n (%)                  | 19 (25.5)   | 5 (22.7)    | 14 (27)               | 0.77    |
| No. of co-morbidities, n (%)                   |             |             |                       |         |
| 0                                              | 35 (47)     | 7 (32)      | 18 (34.5)             | 0.99    |
| 1                                              | 22 (29.7)   | 6 (27.0)    | 16 (31.0)             | 0.31    |
| 2                                              | 14 (19)     | 6 (27.0)    | 8 (15.5)              | 0.33    |
| 3                                              | 7 (9.5)     | 0           | 7 (13.5)              | 0.09    |
| 4                                              | 4 (5.5)     | 2 (9.1)     | 2 (3.8)               | 0.50    |
| 5                                              | 2 (2.7)     | 1 (4.5)     | 1 (2)                 | 0.50    |
| Red Blood Cells, 10^{12} /L, (IQR)             | 4.3 (1.3)   | 4.4 (1.0)   | 4.3 (1.4)             | 0.91    |
| White Blood Cells, 10^{9} /L, (IQR)            | 7.4 (5.6)   | 10.6 (6.5)  | 5.8 (4.5)             | 0.03    |
| Neutrophil-to-Lymphocyte Ratio, (IQR)          | 7.4 (15.4)  | 23.0 (24.0) | 4.7 (6.6)             | <0.0001 |
| Hemoglobin, g/dL, (IQR)                        | 12.5 (3.9)  | 12.6 (3.6)  | 12.3 (3.9)            | 0.78    |
| Platelet count, 10^{5} /L, (IQR)               | 242 (152)   | 254 (103)   | 238 (183)             | 0.48    |
| Lactate Dehydrogenase, U/L, (IQR)              | 251.5 (240.0) | 556.0 (512.0) | 222.0 (94.5)         | <0.0001 |
| C-Reactive Protein, mg/dL, (IQR)               | 5.6 (9.0)   | 6.5 (11.4)  | 4.9 (8.1)             | 0.15    |
| Direct bilirubin, mg/dL, (IQR)                 | 0.1 (0.1)   | 0.2 (0.3)   | 0.1 (0.1)             | 0.0003  |
| Indirect bilirubin, mg/dL, (IQR)               | 0.2 (0.2)   | 0.2 (0.2)   | 0.2 (0.2)             | 0.27    |
| Aspartate transaminase, U/L, (IQR)             | 34.0 (27.0) | 38.0 (32.5) | 31.0 (24.5)           | 0.06    |
| Alanine transaminase, U/L, (IQR)               | 31.0 (35.7) | 32.0 (45.5) | 30.0 (30.0)           | 0.045   |
| Creatinine, mg/dL, (IQR)                       | 0.9 (0.9)   | 0.7 (0.8)   | 1.0 (1.1)             | 0.05    |
| Serum albumin, g/dL, (IQR)                     | 2.4 (0.6)   | 2.4 (0.4)   | 2.4 (1.2)             | 0.87    |
| Prothrombin Time, INR, (IQR)                   | 1.1 (0.1)   | 1.1 (0.2)   | 1.1 (0.2)             | 0.58    |
| Partial thromboplastin time, s, (IQR)          | 24.8 (4.4)  | 22.8 (5.0)  | 25.3 (4.0)            | 0.03    |
| Fibrinogen, mg/dL, (IQR)                       | 544.0 (351.5) | 462.5 (260.2) | 636.0 (238.5)        | 0.0083  |
| D-dimer, ng/mL, (IQR)                          | 1364.0 (5051.5) | 11,936.0 (31,569.0) | 1069.0 (2258.0)     | <0.0001 |
| Factor VIII, %, (IQR)                          | 117.8 (68.0) | 146.2 (55.8) | 95.2 (61.9)           | 0.0032  |

3.2. VWF/ADAMTS-13 Fraction by Care Setting

The VWF activity levels were significantly higher in the patients admitted to the ICU than those measured in the patients admitted to the MW, whereas VWF:antigen (VWF:Ag) and ADAMTS-13 activity were not significantly different (Table 2). However, the VWF/ADAMTS-13 fraction was significantly higher in the ICU patients than in those
admitted to the MW [VWF:Ag/ADAMTS-13 fraction: 5.7 (5.8) vs. 2.9 (1.8), \( p = 0.03 \); VWF:RCo/ADAMTS-13: 6.0 (2.6) vs. 3.4 (2.7), \( p < 0.0001 \)—Mann-Whitney U test] (Table 2).

Table 2. Comparison of VWF and ADAMTS-13 in patients admitted to ICU or medical ward.

| Variables                        | All, \( n = 74 \) | ICU, \( n = 22 \) | Medical Ward, \( n = 52 \) | \( p \) Value |
|----------------------------------|-------------------|-------------------|-----------------------------|---------------|
| vWF:Ag, U/dL, (IQR)              | 223.2 (207.4)     | 494.1 (362.8)     | 222.8 (30.4)                | 0.07          |
| vWF:RCo, U/dL, (IQR)             | 324.1 (265.5)     | 439.8 (195.3)     | 266.5 (196.8)               | <0.0001       |
| ADAMTS-13, U/dL, (IQR)           | 80.0 (30.0)       | 70.0 (20.0)       | 80.0 (30.0)                 | 0.83          |
| vWF:Ag/ADAMTS-13 fraction, (IQR) | 3.1 (4.0)         | 5.7 (5.8)         | 2.9 (1.8)                   | 0.03          |
| vWF:RCo/ADAMTS-13 fraction, (IQR)| 4.1 (3.3)         | 6.0 (2.6)         | 3.4 (2.7)                   | <0.0001       |

Furthermore, VWF:RCo predicted the admission to the ICU \([\text{area under the curve} (AUC) = 0.80, (p < 0.0001), \text{cut-off:}\ 450 \text{ U/dL}]\]. Similarly, the VWF:RCo/ADAMTS-13 and VWF:Ag/ADAMTS-13 fractions were associated with ICU admission [VWF:RCo/ADAMTS-13: AUC = 0.81 (range: 0.70–0.92), \( p < 0.001 \) (Figure 1a); VWF:Ag/ADAMTS-13 fraction: AUC = 0.66 (range: 0.51–0.81), \( p = 0.03 \), Figure 1b]. Values \( \geq 5.7 \) of VWF:RCo/ADAMTS-13 and 5.2 of VWF:Ag/ADAMTS-13 predicted the ICU admission.

Figure 1. ROC curve for the prediction of ICU admission according to VWF:RCo/ADAMTS-13 and VWF:Ag/ADAMTS-13 fractions. (a) ROC curve for the prediction of ICU admission according to VWF:RCo/ADAMTS-13; (b) ROC curve for the prediction of ICU admission according to VWF:Ag/ADAMTS-13.

3.3. Correlation between VWF/ADAMTS-13 and Routine Blood Parameters: Data from the Prospective Cohort

At hospital admission, we found, in the whole group (\( n = 74 \)), a direct relationship between the VWF:RCo/ADAMTS-13 fraction and either D-dimer (Spearman \( r = 0.26, p = 0.03 \)) and or C-reactive protein (CRP) (Spearman \( r = 0.51, p < 0.0001 \)). Furthermore, CRP and D-dimer showed a direct correlation (Spearman \( r = 0.31, p = 0.01 \)).

In the prospective cohort of 54 patients, dynamic changes in the VWF:RCo/ADAMTS-13 fraction directly correlated with variations (expressed as \( \Delta \) value) in CRP concentration (Spearman \( r = 0.54, p = 0.0014 \)). This relationship was statistically significant in both groups [MW: \( p = 0.02 \) (Figure 2a); ICU: \( p = 0.006 \) (Figure 2b)].
Lastly, the VWF:RCo/ADAMTS-13 fraction did not significantly correlate with serum albumin (Spearman test: $p = 0.19$).

### 3.4. VWF/ADAMTS-13 and Mortality

Most fatalities, occurring either in the ICU (6/10, 60%) as well as in the MW (10/16, 62.5%), showed the VWF:RCo/ADAMTS-13 fraction to be above the median values (reported in Table 2) (Figure 3). A cut-off of 6.5 in VWF:RCo/ADAMTS-13 predicted in-hospital mortality with AUC: 0.71, ($p = 0.003$), as demonstrated by receiving operative curve (ROC) analysis (Figure 4).

The D-dimer concentration was significantly higher in non-survivors compared to that calculated in survivors (3461 ng/mL vs. 913.5 ng/mL, Mann–Whitney U test: $p = 0.007$). In addition, the ADAMTS-13 (normal range: 0.40–1.30 U/mL) value was significantly lower in the fatalities (non-survivors: 60.0 U/dL vs. survivors: 80.0 U/dL; Mann–Whitney test: $p = 0.007$).

We did not find any association between other routine laboratory markers and mortality.

![Figure 2](image1.png)

**Figure 2.** Correlation between in-hospital trajectories of VWF:RCo/ADAMTS-13 and CRP according to care setting. (a) Correlation between in-hospital trajectories of VWF:RCo/ADAMTS-13 and CRP in the MW; (b) Correlation between in-hospital trajectories of VWF:RCo/ADAMTS-13 and CRP in the ICU. CRP: C-Reactive Protein.

![Figure 3](image2.png)

**Figure 3.** Scatter plot of VWF:RCo/ADAMTS-13 values according to care setting. Values in ICU and medical ward are shown on the left and right side, respectively. ICU: Intensive Care Unit. MW: Medical Ward.
As expected, we found a higher D-dimer concentration in the patients admitted to the ICU than in those admitted to the MW. This may reflect a more pronounced pro-thrombotic state in ICU patients. The D-dimer concentration shows a significant association with COVID-19 severity, reaching the highest values in the patients admitted to the ICU and in those requiring mechanical ventilation [22,23]. The present results are consistent with the previous findings, as the D-dimer levels observed in the ICU patients were more than 10-fold higher than those observed in the MW patients.

We found a direct correlation between the VWF:RCo/ADAMTS-13 fraction and either CRP or D-dimer. Furthermore, we showed a direct relationship between CRP and D-dimer measured at hospital admission. Interestingly, throughout the entire period of hospitalization, the VWF:RCo/ADAMTS-13 and CRP trajectories correlated. This relationship was statistically significant in both the care settings (MW: \( p = 0.02 \); ICU: \( p = 0.006 \)). Taken together, these findings are consistent with a strong interplay between inflammation, coagulation, and endothelial dysfunction, supporting the hypothetical pathogenesis of thrombo-inflammation in COVID-19 [20]. CRP is a highly sensitive, acute-phase marker, especially in septic patients [24]. An increase in its gene expression is observed during inflammatory states; during infections, specifically interleukin-6 (IL-6) is its main inducer [25]. A relationship between coagulation and inflammation has been previously shown; actually, tissuefactor (TF) plays a central role through the activation of protease-activated receptors (PARs) [26], which, in turn, stimulate cytokine release [27]. Of mention, the cytokine storm, observed in the course of COVID-19, is associated with induction of CRP gene over-expression in later disease stages [28]. It is plausible that the VWF/ADAMTS-13 fraction indicates the progression of endothelial and multi-organ damage. Moreover,
endothelium dysfunction is likely to occur in the later stages of the disease [28], and its variations in the VWF/ADAMTS-13 fraction might be the main laboratory marker.

We did not find a persistent relationship over time between dynamic variations in VWF:RCo/ADAMTS-13 and D-dimer. It is known that COVID-19 patients taking anticoagulants show modifications of D-dimer concentration [29]. All our patients were administered with low-molecular-weight heparin throughout hospitalization, as recommended by the international guidelines. Therefore, we cannot exclude that the pharmacological approach could have influenced this relationship.

A fraction of VWF:RCo/ADAMTS-13 corresponding to 6.5 predicted fatalities independently of the care setting; the higher the fraction was, the higher the risk was. The VWF:RCo/ADAMTS-13 fraction was a good marker of prognosis in our setting. This finding is consistent with the previous observation that micro-vascular occlusions and unfavorable outcomes in infectious diseases might be associated with hyper-activation and the consumption of vascular mediators, such as VWF and ADAMTS-13, remarking the concept that an imbalance in these parameters indicates, in general, a TMA picture [30]. Furthermore, our findings might be also in line with the hypothesis that seriously ill patients with COVID-19 might show a TMA clinical picture [31].

In our series, serum albumin was well below the normal values (2.4 g/L). However, hypoalbuminemia did not seem to affect the disease severity and clinical outcome, which was likely because of the limited number of patients. Albumin is physiologically bound within the glyocalyx of the endothelium, thus contributing to the stability of the layer [32]. It has been hypothesized that hypoalbuminemia is associated with ischemia, likely via endothelium damage and, in turn, activation of the coagulation cascade. Thus, low albumin levels might be associated with thrombotic events in acutely ill patients, reflecting pro-inflammatory or hypercoagulable states [33]. In COVID-19 patients, as well as in other critical settings, low serum albumin is associated with poor outcomes [34–36], and albumin infusion has been suggested to be an effective treatment to improve prognosis in COVID-19 [37,38].

The relatively limited number of patients and the design of the study (i.e., single-center investigation) are the limitations of the present study. Therefore, we must be cautious in generalizing the findings. However, the confirmation of the main findings in the prospective cohort confers robustness to present the data.

5. Conclusions

Predicting the course of a COVID-19 patient’s disease after hospitalization is essential to improve treatment. The VWF/ADAMTS-13 fraction may assist clinicians in the assessment of care intensity in this setting. Our findings add knowledge to understanding COVID-19, contributing to widening the data collection on prognostic biomarkers that are potentially helpful in identifying patients with a worse prognosis.

Author Contributions: Conceptualisation, G.T. and E.G.; writing—original draft preparation, G.T.; data curation, investigation, methodology, A.D.L., G.F., E.C., L.F. (Lucia Fischetti), D.C., E.C., L.F. (Lucia Florio), G.M., A.P.P. and M.M.; supervision, writing—review and editing, E.G. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of CSS-COVID-19 Group (protocol code 46/2020, 8 April 2020).

Informed Consent Statement: Written informed consent, including consent for publication, was obtained from the patient.

Data Availability Statement: The data presented in this study are available on request from the corresponding author.
Acknowledgments: Members of the CSS COVID-19 Group: Paolo Emilio Alboini, Annibale Antonini, Filippo Accella, Giovanni Battista Bochicchio, Cristiano Carbonelli, Massimo Carella, Marco Castori, Antonella Centonze, Gianluca Ciliberti, Massimiliano Copetti, Michele Corritore, Leonardo D’Aloisio, Maria Maddalena D’Errico, Salvatore De Cosmo, Angela de Matteis, Alfredo Del Gaudio, Annabella Di Giorgio, Lazzaro di Mauro, Vincenzo Giambra, Antonio Greco, Andrea Fontana, Vincenzo Inchingolo, Michele Inglese, Maria Labonia, Antonella La Marca, Tiziana Latiano, Maurizio Leone, Evarist Maierolo, Alessandra Mangia, Carmen Marciano, Valentina Massa, Simonetta Massafra, Antonio Mirijello, Grazia Vittoria Orsiu, Nicola Palladino, Rita Perna, Matteo Piemontese, Michele Antonio Prencipe, Pamela Raggi, Maria Grazia Rodriguez, Raffaele Russo, Daniele Sancarlo, Annalisa Simeone, Vincenzo Trischitta, Michele Zarrelli, Pasquale Vaira, Doriane Vergara, Angelo Luigi Vescovi.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Lippi, G.; Plebani, M. Laboratory abnormalities in patients with COVID-2019 infection. Clin. Chem. Lab. Med. 2020, 5, 1131–1134. [CrossRef] [PubMed]
2. Peiró, O.M.; Carrasquer, A.; Sánchez-Gimenez, R.; Lal-Trehan, N.; Del-Moral-Ronda, V.; Bonet, G.; Fort-Gallifa, I.; Picó-Plana, E.; Bastón-Paz, N.; Gutiérrez, C.; et al. Biomarkers and short-term prognosis in COVID-19. Biomarkers 2021, 26, 119–126. [CrossRef]
3. Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020, 395, 1054–1062. [CrossRef]
4. Guiler, N.; Siddiqui, F.; Fareed, J. Is the Reason of Increased D-Dimer Levels in COVID-19 Because of ACE-2-Induced Apoptosis in Endothelium? Clin. Appl. Thromb. Hemost. 2020, 26. [CrossRef] [PubMed]
5. Ladikou, E.E.; Sivaloganathan, H.; Milne, K.M.; Arter, W.E.; Ramasamy, R.; Saad, R.; Stoneham, S.M.; Philips, B.; Eziefula, A.C.; et al. Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy. JTH Open 2021, 4, 174–179. [CrossRef] [PubMed]
6. Mancini, I.; Baronciani, L.; Artoni, A.; Colpani, P.; Biganzoli, M.; Cozzi, G.; Novembrino, C.; Boscolo Anzoletti, M.; De Zan, V.; Pagliari, M.T.; et al. Reduction of ADAMTS13 Levels Predicts Mortality in SARS-CoV-2 Patients. Intern. Emerg. Med. 2020, 15, 861–863. [CrossRef] [PubMed]
7. Tiscia, G.L.; Favuzzi, G.; De Laurenzo, A.; Cappucci, F.; Fischetti, L.; di Mauro, L.; Miscio, G.; Mirijello, A.; Chinni, E.; Grandone, E.; et al. ADAMTS13 deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: Its correlation with development of renal failure. Blood 2006, 107, 528–534. [CrossRef]
8. Tiscia, G.L.; Ostuni, A.; Cascavilla, N.; Cappucci, F.; Scalzulli, P.; Battista, C.; Abrescia, A.; Accella, F.; Buquicchio, C.; Brigante, M.; et al. Validation of PLASMIC score and follow-up data in a cohort of patients with suspected microangiopathies from Southern Italy. J. Thromb. Thrombolysis 2018, 46, 174–179. [CrossRef] [PubMed]
9. Pascreau, T.; Zia-Chahabi, S.; Zuber, B.; Théranak, C.; Farfou, E.; Vasse, M. ADAMTS 13 deficiency is associated with abnormal distribution of von Willebrand factor multimers in patients with COVID-19. Thromb. Res. 2021, 204, 138–240. [CrossRef]
10. Turecek, P.L.; Peck, R.C.; Rangarajan, S.; Reilly-Stitt, C.; Laffan, M.A.; Kazmi, R.; James, I.; Dushianthan, A.; Schrenk, G.; Gritsch, H.; et al. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. Thromb. Res. 2021, 201, 100–112. [CrossRef] [PubMed]
11. Vasileiadis, I.; Politou, M.; Dimopoulos, S.; Rovina, N.; Kyrakopoulos, L.; Kyrakoudi, A.; Tripodaki, E.S.; Koutsouri, T.; Terpos, E.; Koulouris, N.; et al. Variation of endothelium-related hemostatic factors during sepsis. Microcirculation 2018, 25, e12500. [CrossRef] [PubMed]
12. Kremer Hovinga, J.A.; Zeerleder, S.; Kessler, P.; Romani de Wit, T.; van Mourik, J.A.; Hack, C.E.; ten Cate, H.; Reitsma, P.H.; Willemin, W.A.; Lämmlle, B. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. JTH 2007, 5, 2284–2290. [CrossRef]
13. Levi, M.; Scully, M.; Singer, M. The role of ADAMTS-13 in the coagulopathy of sepsis. JTH 2018, 16, 646–651. [CrossRef]
14. Wagner, D.D. The Weibel-Palade body: The storage granule for von Willebrand factor and P-selectin. Thromb. Haemost. 1993, 70, 105–110. [CrossRef]
15. Libby, P.; Lüscher, T. COVID-19 is, in the end, an endothelial disease. Eur. Heart. J. 2020, 41, 3038–3044. [CrossRef] [PubMed]
20. Escher, R.; Breakey, N.; Lämmle, B. Severe COVID-19 infection associated with endothelial activation. *Thromb. Res.* 2020, 190, 62. [CrossRef] [PubMed]

21. Gu, S.X.; Tyagi, T.; Jain, K.; Gu, V.W.; Lee, S.H.; Hwa, J.M.; Kwan, J.M.; Krause, D.S.; Lee, A.I.; Halene, S.; et al. Thrombocytopathy and endotheliopathy: Crucial contributors to COVID-19 thromboinflammation. *Nat. Rev. Cardiol.* 2021, 18, 194–209. [CrossRef] [PubMed]

22. Lippi, G.; Favaloro, E.J. D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis. *Thromb. Haem.* 2020, 120, 876–878. [CrossRef] [PubMed]

23. Hachim, M.Y.; Hachim, I.Y.; Naeem, K.B.; Hannawi, H.; Salmi, I.A.; Hannawi, S. D-dimer, Troponin, and Urea Level at Presentation with COVID-19 can Predict ICU Admission: A Single Centered Study. *Front. Med.* 2020, 7, 585003. [CrossRef] [PubMed]

24. Póvoa, P. C-reactive protein: A valuable marker of sepsis. *Intensive Care Med.* 2002, 28, 235–243. [CrossRef] [PubMed]

25. Sproston, N.R.; Ashworth, J.J. Role of C-Reactive Protein at Sites of Inflammation and Infection. *Front. Immunol.* 2018, 9, 754. [CrossRef] [PubMed]

26. Foley, J.H.; Conway, E.M. Cross Talk Pathways Between Coagulation and Inflammation. *Circ. Res.* 2021, 120, 876–878. [PubMed]

27. Camerer, E.; Huang, W.; Goughlin, S.R. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor Vlla. *Proc. Natl. Acad. Sci. USA* 2000, 97, 5255–5260. [CrossRef]

28. Fajgenbaum, D.C.; June, C.H. Cytokine Storm. *N. Engl. J. Med.* 2020, 383, 2255–2273. [CrossRef]

29. Tassiopoulos, A.K.; Mofakham, S.; Rubano, J.A.; Labropoulos, N.; Bannazadeh, M.; Drakos, P.; Volteas, P.; Cleri, N.A.; Alkadaa, L.N.; Asencio, A.A.; et al. D-Dimer-Driven Anticoagulation Reduces Mortality in Intubated COVID-19 Patients: A Cohort Study with a Propensity-Matched Analysis. *Front. Med.* 2021, 8, 631335. [CrossRef]

30. Gagnano, F.; Sperlongano, S.; Golia, E.; Natale, F.; Bianchi, R.; Crisci, M.; Fimiani, F.; Pariggiano, I.; Diana, V.; Carb, A.; et al. The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. *Mediat. Inflamm.* 2017, 2017, 5620314. [CrossRef]

31. Tiwari, N.R.; Phatak, S.; Sharma, V.R.; Agarwal, S.K. COVID-19 and thrombotic microangiopathies. *Thromb. Res.* 2021, 202, 191–198. [CrossRef] [PubMed]

32. Aldecoa, C.; Llau, J.V.; Nuvials, X.; Artigas, A. Role of albumin in the preservation of endothelial glyocalyx integrity and the microcirculation: A review. *Ann. Intensive Care.* 2020, 10, 85. [CrossRef] [PubMed]

33. Folsom, A.R.; Lutsey, P.L.; Heckbert, S.R.; Cushman, M. Serum albumin and risk of venous thromboembolism. *Thromb. Haemost.* 2010, 104, 100–104. [CrossRef]

34. Vincent, J.L.; Dubois, M.J.; Navickis, R.J.; Wilkes, M.M. Hypoalbuminemia in acute illness: Is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. *Ann. Surg.* 2003, 237, 319–334. [CrossRef]

35. Kheir, M.; Saleem, F.; Wang, C.; Mann, A.; Chua, J. Higher albumin levels on admission predict better prognosis in patients with confirmed COVID-19. *PLoS ONE* 2021, 16, e0248358. [CrossRef]

36. Kendall, H.; Abreu, E.; Cheng, A.L. Serum Albumin Trend Is a Predictor of Mortality in ICU Patients with Sepsis. *Biol. Res. Nurs.* 2019, 21, 237–244. [CrossRef] [PubMed]

37. Ramadori, G. Albumin Infusion in Critically Ill COVID-19 Patients: Hemodilution and Anticoagulation. *Int. J. Mol. Sci.* 2021, 22, 7126. [CrossRef]

38. Violi, F.; Cangemi, R.; Romiti, G.F.; Ceccarelli, G.; Oliva, A.; Alessandrini, F.; Pirro, M.; Pignatelli, P.; Lichtner, M.; Carraro, A.; et al. Is Albumin Predictor of Mortality in COVID-19? *Antioxid. Redox Signal.* 2021, 35, 39–142. [CrossRef]